Alpha Cognition Inc. (ACOGF)

0.4850 0.0000 (0.00%) At close: 02:17PM EDT

Alpha Cognition Inc.

301–1228 Hamilton Street
Vancouver, BC V6B 6L2
Canada

https://www.alphacognition.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael E. McFadden	CEO & Director	429.78k	N/A	1967
Mr. Kenneth Anthony Cawkell B.A., LL.B.	Founder, Special Advisor, Corp. Sec. & Director	264.6k	N/A	1951
Dr. Denis G. Kay Ph.D.	Chief Scientific Officer	238.57k	N/A	1957
Ms. Lauren D'Angelo M.B.A.	Chief Commercial Officer	312.4k	N/A	N/A
Mr. Donald A. Kalkofen B.A.	Chief Financial Officer	N/A	N/A	1964
Ms. Colleen Johns	Sr. VP of Product Devel.	N/A	N/A	N/A
Dr. Cedric O'Gorman M.B.A., M.D., MBA	Chief Medical Officer	N/A	N/A	1975

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Corporate Governance

Alpha Cognition Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.